Methylergometrine
- Generic Name
- Methylergometrine
- Brand Names
- Methergine
- Drug Type
- Small Molecule
- Chemical Formula
- C20H25N3O2
- CAS Number
- 113-42-8
- Unique Ingredient Identifier
- W53L6FE61V
- Background
A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed)
- Indication
For the prevention and control of excessive bleeding following vaginal childbirth
- Associated Conditions
- Angina Pectoris, Variant, Postpartum Haemorrhage (PPH), Postpartum uterine subinvolution, Uterine Atony, Uterine Hemorrhage
- Associated Therapies
- -
Prophylactic Methylergonovine for Twin Cesarean
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 66
- Registration Number
- NCT05772156
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Multimodal Uterotonics at the Time of Cesarean Section in Laboring Patients
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Cynthia Wong
- Target Recruit Count
- 160
- Registration Number
- NCT03904446
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
Intravenous Versus Intramuscular Administration of Methylergonovine for Uterine Contraction in Cesarean Sections
Early Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2017-10-05
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Johns Hopkins University
- Registration Number
- NCT03303235
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
Uterotonic Prophylaxis Trial
- First Posted Date
- 2015-04-06
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 284
- Registration Number
- NCT02408965
- Locations
- 🇺🇸
SFGH Women's Options Center, San Francisco, California, United States
Reduction of Endometritis After Cesarean Section With the Routine Use of Methergine
- First Posted Date
- 2009-03-10
- Last Posted Date
- 2012-09-19
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 44
- Registration Number
- NCT00858832
- Locations
- 🇺🇸
Tampa General Hospital, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath